Methods for Diagnosis, Prognosis and Monitoring of Breast Cancer and Reagents Therefor
AssigneeGarvan Institute of Medical Research
InventorsSusan Clark, Elena Zotenko, Clare Stizaker, Glenn Francis
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen receptor (ER) negative breast cancer, ER positive breast cancer, triple negative breast cancer (TNBC) and other subtypes of breast cancer.
Claims35
A method for the diagnosis of breast cancer in a subject, said method comprising:
- (i) determining the methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject;
- and
- (ii) identifying differential methylation of said one or more CpG dinucleotide sequences in the test sample relative to a reference level of methylation for the corresponding one or more CpG dinucleotide sequences,
- wherein differential methylation of said one or more CpG dinucleotide sequences in the test sample relative to the reference level is indicative of the subject having breast cancer.
A method for prognosis of, predicting the therapeutic outcome of and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject, said method comprising:
- (i) determining differential methylation of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 3 in the subject relative to a reference level of methylation for the corresponding one or more CpG dinucleotide sequences;
- and
- (ii) correlating the differential methylation determined at (i) with a prognosis of the TNBC in the subject.
A kit for diagnosing breast cancer in a subject, said kit comprising:
- (i) one or more reagents to determine the methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject;
- and
- (ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.
A kit for diagnosing estrogen receptor negative (ER−ve) breast cancer in a subject, said kit comprising:
- (i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject;
- and
- (ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.
A kit for diagnosing Triple Negative Breast Cancer (TNBC) in a subject, said kit comprising:
- (i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject;
- and
- (ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.
A kit for prognosis of, predicting the therapeutic outcome of, and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject;
- said kit comprising:
- (i) one or more reagents to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject;
- and
- (ii) a reference material which provides a reference level of methylation of the corresponding one or more CpG dinucleotide sequences.
Use of one or more reagents in the preparation of a medicament for diagnosing breast cancer in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject.
Use of one or more reagents in the preparation of a medicament for diagnosing estrogen receptor negative (ER−ve) breast cancer in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 1 in a test sample obtained from the subject.
Use of one or more reagents in the preparation of a medicament for diagnosing Triple Negative Breast Cancer (TNBC) in a subject suspected of having TNBC, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in Table 2 in a test sample obtained from the subject.
Use of one or more reagents in the preparation of a medicament for prognosis of, predicting the therapeutic outcome of, and/or monitoring the progression of, Triple Negative Breast Cancer (TNBC) in a subject, wherein the one or more reagents is/are configured to determine methylation status of one or more CpG dinucleotide sequences within one or more genomic regions defined in 2 in a test sample obtained from the subject.
Dependencies are inferred from the claim text.